Phase 2, open-label, randomized study evaluating the safety and efficacy of three different doses of oral panobinostat (Farydak®in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

Type of Cancer
Multiple Myeloma

Site
Freehold, Howell

Sponsor
NOVARTIS

Protocol Number
CLBH589D2222

To Learn More Call
201-510-0910